Press release
Signatera™ Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows
Signatera outperformed all available risk stratification tools in postoperative and post-definitive therapy settings AUSTIN, Texas--(BUSINESS WIRE)-- Natera,
About this update from Natera, Inc.
[{"type":"text","content":"\nSignatera outperformed all available risk stratification tools in postoperative and post-definitive therapy settings\n\n\n AUSTIN, Texas--(BUSINESS WIRE)--\nNatera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a new study in the Journal of Clinical Oncology Precision Oncology (JCO PO), validating Signatera for recurrence monitoring and treatment response assessment in patients with early-stage uterine cancer.\n\n\nUterine cancer is the most common gynecologic malignancy in the United States.1 While most patients are diagnosed with early-stage disease and have a low risk of recurrence, many may have an up to 30% risk of recurrence despite uterine-confined disease.2 For patients with early-stage, high or higher-intermediate risk uterine cancer, there are limited tools to individualize recurrence risk and direct therapy.\n\n\nThis recently published, real-world, multi-center, retrospective study analyzed 233 plasma samples from 61 patients with stage I/II uterine cancer who had undergone surgical staging.\n\n\nKey findings from the study include:\n\n\n\nSignatera positivity was highly prognostic of recurrence in both the postoperative (HR=7.6; p=0.003) and post-definitive therapy (HR=25.4, p=0.0009) settings.\n\n\n\nSignatera status was the most prognostic risk factor, outperforming conventional clinicopathologic factors.\n\n\n\nAmong patients with Signatera surveillance testing, 100% tested positive before clinically confirmed recurrence, with a median lead time of 3.1 months. None of the serially Signatera-negative patients experienced recurrence.\n\n\n\nAdditionally, the study further supports the conclusions of Recio et al. 20243, which established postoperative and longitudinal Signatera testing as a highly prognostic tool in early-stage uterine cancer.\n\n\n“In our study, ctDNA positivity was more prognostic of recurrence than any of the traditional risk stratification factors used in practice, and importantly, it is individualized for every patient,” said Michael Toboni, M.D., MPH, gynecologic oncologist at the University of Alabama at Birmingham and principal investigator of the study. “These findings support the potential utility of ctDNA testing as a way to de-escalate and ultimately reduce unnecessary and toxic treatment in early-stage patients.”\n\n\n...